Key result
Targeting soluble adenylyl cyclase (sAC) with specific inhibitors offers a promising strategy for developing safe, non-hormonal, on-demand contraceptives for both men and women.
Why the study?
This review details why soluble adenylyl cyclase is uniquely druggable and outlines ways to target it for novel forms of male and female contraception.
Answers are grounded in this paper and cite their sources.
Soluble adenylyl cyclase (sAC) presents a uniquely druggable target for the development of novel, non-hormonal, on-demand male and female contraceptives.
In humans, the prototypical second messenger cyclic AMP is produced by 10 adenylyl cyclase isoforms, which are divided into two classes. Nine isoforms are G protein coupled transmembrane adenylyl cyclases (tmACs; ADCY1-9) and the 10th is the bicarbonate regulated soluble adenylyl cyclase (sAC; ADCY10). This review details why sAC is uniquely druggable and outlines ways to target sAC for novel forms of male and female contraception.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2022) conducted a review in Contraception. Soluble adenylyl cyclase (sAC) inhibitors was evaluated. Targeting soluble adenylyl cyclase (sAC) with specific inhibitors offers a promising strategy for developing safe, non-hormonal, on-demand contraceptives for both men and women.
Synapse has enriched 10 related papers. Consider them for comparative context: